NCT05558319: Phase 3: (GEM21menos65) Extended VRD Plus vs Isa-VRD vs Isa-V-Iberdomide - NDMM - ASCT
NCT05257083: Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT- NDMM CARTITUDE-6
NCT05561387: Phase 3: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma NDMM
NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)
NCT05552222: Phase 3: Teclistamab-Daratumumab-Len (Tec-DR) Vs Dara-Len-dex (DRd) (MajesTEC-7) NDMM
NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) + Dex
NCT05317416: Phase 3: Elranatamab Versus Lenalidomide in Patients With NDMM post ASCT - MagnetisMM-7
NCT05243797: Phase 3: EMN 30 - Tec + Len Vs Len Alone NDMM as Maint. Therapy Post ASCT (MajesTEC-4)
NCT05259839: Phase 1: IV Infused ABBV-383 With Anti-Cancer Regimens for Relapsed/Refractory Myeloma
NCT04934475: Phase 3 - IFM 2020-02 Minimal Residual Disease Adapted Strategy (MIDAS) KRD-Isatuximab
NCT04751877: Phase 3 - Isa-Rd +/- Bortezomib Non Frail NTE Myeloma Elderly Patients IFM2020-05
NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902
NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma
The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of RRMM treated with IRd
NCT04808037: Phase 1/2: Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM (BelaRd)
NCT05060627: Phase 1/2: Belantamab Mafodotin + Kd RRMM Multiple Myeloma, Refractory to Lenalidomide
NCT05123131: Phase 2: Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma (Isa-RVD)
NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Tx RRMM
NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in RRMM Myeloma
NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)
NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST)
NCT04802356: Phase 2: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma
NCT04891809: Phase 2 - Isatuximab in Combination With Rd Compared to Rd in Elderly NDMM
NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction & Lenalidomide Maint
NCT04717700: Phase 2: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dex in TIE NDMM
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
NCT04822337: Phase 1/2 - Study of Carfilzomib, Len, Dex & Belantamab Mafodotin in Multiple Myeloma
NCT04674514: Phase 1/2: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS RRMM Myeloma
NCT04497961: Phase 2: A Study of Health-Related Quality of Life with Daratumumab or Lenalidomide
NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
NCT04566328: Phase 3 - Testing the Use of Combination Therapy in NDMM, the EQUATE Trial - EAA181
NCT04653246: Phase 2: Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
NCT04268498: Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: phase III GMMG-MM5 trial
NCT04513639: Phase 2/3: The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study
NCT04270409: Phase 3 - Isatuximab in Combination With Lenalidomide and Dex High-risk SMM (ITHACA)
NCT04430894: Phase 2: KRDI in Transplant-Eligible MM
NCT04483739: Phase 3: EMN 24 - Isa-KRd vs KRd New Multiple Myeloma Eligible for ASCT - IsKia TRIAL
NCT04052880 : Phase 2 - SubQ Dara + Dose-Atten. Bortezomib, Lenalidomide, Dex New MM >70 years
NCT04196491: Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM) (KarMMa-4)
NCT03984097: Phase 1: A Study to Evaluate Subcutaneous TAK-079 Added to Standard Regimens NDMM
NCT04096066: Phase 3: EMN 20 - A Trial That Compare Two Treatments TIE - NDMM - KRd Vs Rd
NCT03901963: Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)
NCT04071457: Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maint. NDMM DRAMMATIC
NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in TIE NDMM
NCT04091126: Phase 1 - Belantamab Mafodotin + Standard of Care New Multiple Myeloma (DREAMM 9) NDMM
NCT03937635: Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma DETER-SMM